Menu Search
Equities

Biomerieux SA

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BIM:VIE

Biomerieux SA

Actions
  • Price (EUR)96.40
  • Today's Change-0.600 / -0.62%
  • Shares traded0.00
  • 1 Year change-15.88%
  • Beta0.8491
Data delayed at least 15 minutes, as of Feb 06 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Biomerieux SA is a France-based company that specializes in the field of in-vitro diagnostics for medical and industrial applications. The Company designs, develops, manufactures and sells systems used in clinical applications, such as for the diagnosis of tuberculosis, respiratory infections, among others and industrial applications, such as for the analysis of industrial or environmental samples. The Company also provides its customers with related services for the installation and maintenance of instruments, and training for product users. BioMerieux SA operates through its numerous subsidiaries in various countires, including bioMerieux Deutschland GmbH, bioMerieux Austria GmbH, Advencis, bioMerieux Benelux SA/NV, as well as BioFire Diagnostics Inc., chromID CARBA SMART and new bi-plate Petri dish.

  • Revenue in EUR (TTM)4.12bn
  • Net income in EUR377.90m
  • Incorporated1967
  • Employees14.75k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		BIM:PAR since
announced		Transaction
value
Accellix IncDeal completed22 Jan 202622 Jan 2026Deal completed-9.20%41.14m
Data delayed at least 15 minutes, as of Feb 06 2026 16:35 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.